Author

Douglas Kung

Georgetown UniversityORCID 0000-0001-5062-5373Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Alec T. McIntoshiD· 1 shared Andrew Hoy· 1 shared Anqi Feng· 1 shared Arun KrishnarajiD· 1 shared Aykut ÜreniD· 1 shared Gong TangiD· 1 shared Katelyn R. AlleyiD· 1 shared Lu JiniD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alec T. McIntoshORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Molecular BiologybioRxivPreprintSep 16, 2026

Transcriptome-wide mapping reveals a non-canonical RNA-dependent mechanism of platinum cancer drugs

Arun Krishnaraj, Xinrui Wei, Richi Thakral…·Sreejith J. Nair

The paper identifies cisplatin as an RNA binder and shows its cytotoxicity is partially mediated through RNA binding, revealing a noncanonical mechanism of action.

1 citation

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 10, 2026

Impact of Trastuzumab and Pertuzumab on HER2 Localization and the Estrogen Receptor Cistrome in ER+/HER2+ Breast Cancer

Stanley Tam, Shaymaa Bahnassy, Lu Jin…·Rebecca Baab Riggins

This study examines how anti-HER2 therapy affects HER2 localization and ER genomic binding in ER+/HER2+ breast cancer, finding ER redistribution correlates with treatment resistance.

DOI 10.64898/2026.09.07.749891

humanChIP-seq

𝕏 PostBluesky